Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
GrowGeneration
GRWG
$90.7M
| $236K | ﹤0.01% |
+94,200
| New | +$231K |
|
|
KGEI
3077
Kolibri Global Energy
KGEI
$184M
| $236K | ﹤0.01% |
+61,250
| New | +$256K |
|
3078
Fidelity Total Bond ETF
FBND
$27.2B
| $235K | ﹤0.01% |
+5,100
| New | +$225K |
|
3079
SB Financial Group
SBFG
$169M
| $234K | ﹤0.01% |
+15,243
| New | +$210K |
|
3080
Solid Biosciences
SLDB
$817M
| $234K | ﹤0.01% |
38,071
+9,501
| +33% | +$30.4K |
|
3081
MVB Financial
MVBF
$387M
| $232K | ﹤0.01% |
10,300
+800
| +8% | +$16.9K |
|
3082
Neumora Therapeutics
NMRA
$304M
| $232K | ﹤0.01% |
+13,600
| New | +$167K |
|
|
AKYA
3083
DELISTED
Akoya BioSciences
AKYA
| $231K | ﹤0.01% |
47,400
-165,200
| -78% | -$686K |
|
3084
Cue Biopharma
CUE
$115M
| $230K | ﹤0.01% |
2,907
+914
| +46% | +$65.3K |
|
|
LYRA
3085
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $230K | ﹤0.01% |
878
-118
| -12% | -$21.4K |
|
3086
Invesco WilderHill Clean Energy ETF
PBW
$426M
| $229K | ﹤0.01% |
+7,700
| New | +$213K |
|
|
CUTR
3087
DELISTED
Cutera, Inc.
CUTR
| $228K | ﹤0.01% |
64,793
-96,405
| -60% | -$294K |
|
3088
Lifecore Biomedical
LFCR
$185M
| $227K | ﹤0.01% |
36,700
-32,600
| -47% | -$226K |
|
|
XOMA
3089
DELISTED
Xoma
XOMA
| $227K | ﹤0.01% |
12,296
-5,909
| -32% | -$97.3K |
|
3090
First Internet Bancorp
INBK
$255M
| $225K | ﹤0.01% |
9,319
-28,470
| -75% | -$550K |
|
|
TBHC
3091
DELISTED
The Brand House Collective
TBHC
| $225K | ﹤0.01% |
74,400
-21,800
| -23% | -$47.7K |
|
|
PET
3092
DELISTED
Wag!
PET
| $225K | ﹤0.01% |
128,186
+35,947
| +39% | +$63.6K |
|
|
BLTE
3093
Belite Bio
BLTE
$6.56B
| $224K | ﹤0.01% |
+4,900
| New | +$188K |
|
3094
Immix Biopharma
IMMX
$668M
| $224K | ﹤0.01% |
+32,400
| New | +$147K |
|
|
FPAY
3095
DELISTED
FlexShopper
FPAY
| $223K | ﹤0.01% |
133,607
-18,517
| -12% | -$23.9K |
|
3096
PEDEVCO
PED
$142M
| $223K | ﹤0.01% |
14,455
-3,600
| -20% | -$63.3K |
|
3097
Direxion Daily FTSE China Bear 3X ETF
YANG
$89.2M
| $223K | ﹤0.01% |
+870
| New | +$213K |
|
3098
BGSF Inc
BGSF
$58.9M
| $222K | ﹤0.01% |
23,600
+2,300
| +11% | +$21.8K |
|
3099
CervoMed
CRVO
$26.2M
| $222K | ﹤0.01% |
29,033
-200
| -0.7% | -$1.73K |
|
3100
Dare Bioscience
DARE
$21.1M
| $222K | ﹤0.01% |
59,950
+4,050
| +7% | +$18.5K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.